NCCN Receives Funding for Policy and Advocacy Fellow
Through funding from EMD Serono, NCCN is instituting a Policy and Advocacy Fellowship designed for implementation of policy programs that will enhance access to and delivery of quality oncology care in the United States and globally.
FORT WASHINGTON, PA — The National Comprehensive Cancer Network® (NCCN®) is instituting a new Policy and Advocacy Fellowship to support access to and delivery of high-quality cancer care worldwide as part of its Oncology Policy Program. The two-year Fellowship is made possible through funding from EMD Serono, the biopharma business of Merck KGaA, Darmstadt, Germany in the United States and Canada.
“The patient experience in the United States is in large part shaped by health policy, and health policy in the United States has a large impact on the global policy landscape. NCCN has the unique ability to provide real-world recommendations with implications for public policy, process, and implementation at the global level. The Policy and Advocacy Fellow will also bolster NCCN’s impact on U.S. health policy, as well as further infuse the patient advocacy voice into the oncology policy arena,” said Robert W. Carlson, MD, Chief Executive Officer, NCCN.
The NCCN Policy and Advocacy Fellowship is designed to encourage a next generation leader in the early stages of their career to research, develop, advocate, facilitate, and communicate the implementation of oncology policy programs that further NCCN’s mission to improve the quality, effectiveness, and efficiency of cancer care so that patients can live better lives and vision to be the world’s leader in defining and advancing high-quality, high-value cancer care. Among various responsibilities, the Policy/Advocacy Fellow will track legislation and global cancer-policy issues and opportunities relevant to the NCCN mission and vision and act as point of contact for NCCN with cancer-policy and advocacy coalitions, manage the NCCN Policy Advisory Group, and plan and implement the NCCN Policy Summit Series.
“Our support for people living with cancer and their loved ones goes beyond the compounds we’re developing or any medicine we hope to provide,” said Gary Zieziula, President and Managing Director, EMD Serono. “We believe that we have an obligation to take a broad view of the communities we serve and to meet their specific needs. The NCCN Policy and Advocacy Fellowship is a perfect example of meeting that need within the cancer community.”
For more information about the NCCN Oncology Policy Program, visit NCCN.org/policy.
###
About the National Comprehensive Cancer Network
The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 27 of the world’s leading cancer centers devoted to patient care, research, and education, is dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers.
The NCCN Member Institutions are: Fred & Pamela Buffett Cancer Center, Omaha, NE; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; City of Hope Comprehensive Cancer Center, Los Angeles, CA; Dana-Farber/Brigham and Women’s Cancer Center | Massachusetts General Hospital Cancer Center, Boston, MA; Duke Cancer Institute, Durham, NC; Fox Chase Cancer Center, Philadelphia, PA; Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, WA; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; Mayo Clinic Cancer Center, Phoenix/Scottsdale, AZ, Jacksonville, FL, and Rochester, MN; Memorial Sloan Kettering Cancer Center, New York, NY; Moffitt Cancer Center, Tampa, FL; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, Columbus, OH; Roswell Park Cancer Institute, Buffalo, NY; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO; St. Jude Children’s Research Hospital/The University of Tennessee Health Science Center, Memphis, TN; Stanford Cancer Institute, Stanford, CA; University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL; UC San Diego Moores Cancer Center, La Jolla, CA; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; University of Colorado Cancer Center, Aurora, CO; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; The University of Texas MD Anderson Cancer Center, Houston, TX; University of Wisconsin Carbone Cancer Center, Madison, WI; Vanderbilt-Ingram Cancer Center, Nashville, TN; and Yale Cancer Center/Smilow Cancer Hospital, New Haven, CT.
Clinicians, visit NCCN.org. Patients and caregivers, visit NCCN.org/patients. Media, visit NCCN.org/news.
About EMD Serono, Inc.
EMD Serono is the North America biopharma business of Merck KGaA, Darmstadt, Germany - a leading science and technology company - focused exclusively on specialty care. For more than 40 years, the business has integrated cutting-edge science, innovative products and industry-leading patient support and access programs. EMD Serono has deep expertise in neurology, fertility and endocrinology, as well as a robust pipeline of potential therapies in oncology, immuno-oncology and immunology as R&D focus areas. Today, the business has more than 1,200 employees around the country with commercial, clinical and research operations based in the company’s home state of Massachusetts. www.emdserono.com
About Merck KGaA, Darmstadt, Germany
All Merck KGaA, Darmstadt, Germany, press releases are distributed by e-mail at the same time they become available on the EMD Group Website. In case you are a resident of the USA or Canada please go to www.emdgroup.com/subscribe to register again for your online subscription of this service as our newly introduced geo-targeting requires new links in the email. You may later change your selection or discontinue this service.
Merck KGaA, Darmstadt, Germany, is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2015, Merck KGaA, Darmstadt, Germany, generated sales of € 12.85 billion in 66 countries.
Founded in 1668, Merck KGaA, Darmstadt, Germany, is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck KGaA, Darmstadt, Germany operates as EMD Serono, MilliporeSigma and EMD Performance Materials in the United States and Canada.
Katie Kiley Brown, NCCN
215.690.0238
Tags: